Protinádorová vakcína dendritickými buňkami naloženými Id proteinem u nemocných s mnohočetným myelomem, interní analýza bezpečnosti podání

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Anticancer Id-protein Loaded Dendritic Cells Vaccine in Patiens with Mulptiple Myeloma, An Internal Safety Evaluation
Authors

ZAHRADOVÁ Lenka OČADLÍKOVÁ Darina KOVÁŘOVÁ Lucie BÜCHLER Tomáš KREJČÍ Marta ADAM Zdeněk POUR Luděk KŘIVANOVÁ Andrea SANDECKÁ Viera PENKA Miroslav VORLÍČEK Jiří MICHÁLEK Jaroslav HÁJEK Roman

Year of publication 2008
Type Article in Proceedings
Conference Edukační sborník, XXXII. Brněnské onkologické dny a XXII. Konference pro nelékařské zdravotnické pracovníky
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords multiple myeloma; dendritic cells; immunotherapy; idiotype
Description Patients (pts) with multiple myeloma not requiring systemic therapy were enrolled to the study. Pts received 6 doses of dendritic cells (DCs) loaded with autologous Id-protein every 4 weeks. Autologous mature DCs derived from peripherial blood monocytes were prepared in vitro and loaded with Id-protein. A clinical response was evaluated by measuring the monoclonal immunoglobulin levels. An immune response was monitored by flow cytometry, the production of interferon gamma (evaluated by Elispot) by myeloma-reactive T lymphocytes and a delayed type hypersensitivity test. Vaccination was well tolerated, no significant toxicities were observed in first 4 pts. A local reaction was observed in all pts and disappeared in 2-6 days. The immune response was noticed in 3 pts. No clinical response was observed. Vaccination with Id-protein loaded autologous DCs is a safe therapeutic strategy with no significant side effects. The trial will continue until a total number of 12 pts will be enrolled.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.